X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (4124) 4124
Magazine Article (11) 11
Book / eBook (8) 8
Conference Proceeding (4) 4
Book Review (1) 1
Publication (1) 1
Web Resource (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (2766) 2766
male (2128) 2128
animals (1987) 1987
antiparkinson agents - pharmacology (1986) 1986
parkinson disease - drug therapy (1967) 1967
parkinson's disease (1807) 1807
antiparkinson agents - therapeutic use (1804) 1804
pharmacology & pharmacy (1494) 1494
female (1388) 1388
neurosciences (1237) 1237
clinical neurology (1035) 1035
middle aged (972) 972
rats (966) 966
aged (955) 955
levodopa (863) 863
antiparkinson agents - adverse effects (860) 860
levodopa - therapeutic use (802) 802
antiparkinson agents - administration & dosage (707) 707
levodopa - pharmacology (682) 682
parkinson disease - physiopathology (618) 618
parkinsons-disease (573) 573
dopamine (572) 572
l-dopa (503) 503
levodopa - adverse effects (495) 495
dose-response relationship, drug (475) 475
disease models, animal (463) 463
adult (458) 458
neurology (440) 440
mice (427) 427
parkinson’s disease (404) 404
dopamine - metabolism (399) 399
levodopa - administration & dosage (397) 397
antiparkinson agents - pharmacokinetics (389) 389
motor activity - drug effects (386) 386
rats, sprague-dawley (376) 376
psychiatry (373) 373
parkinson disease - metabolism (349) 349
double-blind (341) 341
parkinsonian disorders - drug therapy (327) 327
time factors (324) 324
dopa (322) 322
basal ganglia (310) 310
treatment outcome (309) 309
motor fluctuations (301) 301
medicine & public health (295) 295
analysis (285) 285
parkinsons disease (280) 280
drug therapy, combination (279) 279
movement disorders (272) 272
pharmacology/toxicology (266) 266
parkinson disease - complications (265) 265
corpus striatum - drug effects (262) 262
dyskinesia (260) 260
aged, 80 and over (251) 251
neurons (241) 241
disease (239) 239
brain - drug effects (238) 238
corpus striatum - metabolism (238) 238
rats, wistar (236) 236
neuroprotective agents - pharmacology (232) 232
brain (229) 229
dopamine agonists - therapeutic use (229) 229
dopamine agonists - pharmacology (224) 224
behavior, animal - drug effects (222) 222
drug interactions (222) 222
drug therapy (220) 220
levodopa - pharmacokinetics (220) 220
substantia-nigra (220) 220
pharmacokinetics (219) 219
parkinson disease (211) 211
double-blind method (210) 210
neurodegenerative diseases (200) 200
antiparkinson agents - chemistry (197) 197
brain - metabolism (196) 196
drug combinations (196) 196
oxidative stress (194) 194
severity of illness index (192) 192
oxidopamine (191) 191
neurons - drug effects (182) 182
neuroprotection (182) 182
therapy (179) 179
apomorphine - pharmacology (177) 177
dyskinesia, drug-induced - drug therapy (176) 176
antiparkinson agents (174) 174
biochemistry & molecular biology (168) 168
mice, inbred c57bl (168) 168
parkinson disease - pathology (168) 168
antiparkinsonian agents (166) 166
mptp (164) 164
apomorphine (162) 162
striatum (160) 160
6-hydroxydopamine (155) 155
research (155) 155
pramipexole (154) 154
parkinson disease, secondary - chemically induced (152) 152
dyskinesia, drug-induced - etiology (151) 151
phenols (151) 151
parkinsonian disorders - physiopathology (150) 150
catechol o-methyltransferase inhibitors (147) 147
substantia nigra - drug effects (146) 146
more...
Library Location Library Location
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (3986) 3986
Japanese (50) 50
German (45) 45
Russian (45) 45
French (30) 30
Spanish (28) 28
Polish (11) 11
Chinese (6) 6
Hungarian (4) 4
Italian (4) 4
Portuguese (4) 4
Dutch (3) 3
Finnish (2) 2
Ukrainian (2) 2
Croatian (1) 1
Czech (1) 1
Norwegian (1) 1
Swedish (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Journal of Neuroscience, ISSN 0270-6474, 02/2005, Volume 25, Issue 8, pp. 2157 - 2165
Regulator of G-protein signaling 9-2 (RGS9-2), a member of the RGS family of G GTPase accelerating proteins, is expressed specifically in the striatum, which... 
DEP domain | Striatum | Antipsychotic | RGS9 | dopamine receptor | Dyskinesia | Antipsychotic Agents - toxicity | RGS Proteins - genetics | Reserpine - toxicity | Sulpiride - pharmacology | Antiparkinson Agents - pharmacology | Dyskinesia, Drug-Induced - physiopathology | Humans | Recombinant Fusion Proteins - physiology | Antiparkinson Agents - toxicity | RGS Proteins - physiology | Dopamine Agents - therapeutic use | Receptors, Dopamine D2 - metabolism | Antiparkinson Agents - therapeutic use | Transfection | Apomorphine - pharmacology | Dopamine - physiology | Dopamine Agents - pharmacology | RGS Proteins - deficiency | Dopamine Antagonists - toxicity | Reserpine - pharmacology | Female | Haloperidol - pharmacology | Receptors, G-Protein-Coupled - physiology | Protein Structure, Tertiary | Corpus Striatum - physiopathology | Parkinson Disease - physiopathology | Receptors, Dopamine D2 - genetics | Mice, Knockout | Protein Interaction Mapping | Patch-Clamp Techniques | Animals | Movement Disorders - physiopathology | Dopamine Antagonists - pharmacology | 2,3,4,5-Tetrahydro-7,8-dihydroxy-1-phenyl-1H-3-benzazepine - pharmacology | Corpus Striatum - drug effects | Mice | Quinpirole - pharmacology | Antipsychotic Agents - pharmacology | Movement Disorders - genetics | Haloperidol - toxicity | Subcellular Fractions - chemistry | Receptors, Dopamine D1 - genetics | striatum | Neurobiology of Disease | antipsychotic | dyskinesia | D2 dopamine receptor
Journal Article
Lancet neurology, ISSN 1474-4422, 2016, Volume 15, Issue 2, pp. 154 - 165
Journal Article
Clinical therapeutics, ISSN 0149-2918, 2007, Volume 29, Issue 9, pp. 1825 - 1849
...: The aim of this study was to review the pharmacology, tolerability, and clinical efficacy of rasagiline in the treatment of PD. Methods: MEDLINE (1966-April 2007... 
Internal Medicine | Medical Education | rasagiline | Parkinson's disease | propargylamine | neuroprotection | monoamine oxidase | selegiline | CONTROLLED-TRIAL | SEROTONIN SYNDROME | MAO-B INHIBITOR | MPTP-INDUCED NEUROTOXICITY | MOTOR FLUCTUATIONS | MITOCHONDRIAL PERMEABILITY TRANSITION | IN-VIVO | DOUBLE-BLIND | PHARMACOLOGY & PHARMACY | L-DEPRENYL | NEUROBLASTOMA SH-SY5Y CELLS | rasagilme | Indans - adverse effects | Neuroprotective Agents - therapeutic use | Antiparkinson Agents - pharmacology | Humans | Selegiline - pharmacology | Parkinson Disease - drug therapy | Indans - therapeutic use | Monoamine Oxidase Inhibitors - administration & dosage | Antiparkinson Agents - therapeutic use | Drug Interactions | Neuroprotective Agents - pharmacology | Indans - administration & dosage | Neuroprotective Agents - adverse effects | Drug Therapy, Combination | Neuroprotective Agents - administration & dosage | Selegiline - therapeutic use | Monoamine Oxidase Inhibitors - therapeutic use | Monoamine Oxidase Inhibitors - pharmacology | Selegiline - adverse effects | Monoamine Oxidase Inhibitors - adverse effects | Food-Drug Interactions | Antiparkinson Agents - adverse effects | Selegiline - administration & dosage | Antiparkinson Agents - administration & dosage | Indans - pharmacology | Oxidases | Medical colleges | Drug therapy | Analysis
Journal Article
Neuropsychopharmacology (New York, N.Y.), ISSN 0893-133X, 01/2014, Volume 39, Issue 1, pp. 131 - 155
There is serious interest in understanding the dynamics of the receptor-receptor and receptor-protein interactions in space and time and their integration in... 
receptorreceptor interactions | moonlighting | neuropsychiatric disorders | G protein-coupled receptors | neurotherapeutic targets | heterodimerization | PSYCHIATRY | RESONANCE ENERGY-TRANSFER | FIBROBLAST-GROWTH-FACTOR | NEUROSCIENCES | INDUCED MOTOR COMPLICATIONS | receptor-receptor interactions | ADENOSINE A(2A) RECEPTORS | DOPAMINE D2 RECEPTORS | HIGHER-ORDER OLIGOMERS | ANTIPSYCHOTIC-DRUGS | PHARMACOLOGY & PHARMACY | CENTRAL-NERVOUS-SYSTEM | PARKINSONS-DISEASE | MOLECULAR-MECHANISMS | Schizophrenia - metabolism | Antiparkinson Agents - pharmacology | Receptors, G-Protein-Coupled - metabolism | Humans | Drug Discovery - methods | Parkinson Disease - drug therapy | Antidepressive Agents - therapeutic use | Antiparkinson Agents - therapeutic use | Cocaine - pharmacology | Depression - drug therapy | Protein Interaction Mapping - methods | Depression - metabolism | Animals | Cocaine-Related Disorders - metabolism | Antipsychotic Agents - therapeutic use | Antidepressive Agents - pharmacology | Cocaine-Related Disorders - drug therapy | Parkinson Disease - metabolism | Antipsychotic Agents - pharmacology | Schizophrenia - drug therapy | Cocaine - adverse effects | Molecular Targeted Therapy - methods | Allosteric properties | receptor–receptor interactions | Receptor Pharmacology | Dopamine | Development | Neuropharmacology | Drug Discovery | Neuropsychopharmacology Reviews
Journal Article
Toxicology and applied pharmacology, ISSN 0041-008X, 06/2016, Volume 301, pp. 42 - 49
Journal Article